Plandai Biotechnology (Plandai Biotechnology) Operating Income : $-0.71 Mil (TTM As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Operating Income?

Plandai Biotechnology's Operating Income for the six months ended in Jun. 2023 was $-0.71 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.71 Mil.

Warning Sign:

Plandai Biotechnology Inc has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Plandai Biotechnology's Operating Income for the six months ended in Jun. 2023 was $-0.71 Mil. Plandai Biotechnology's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Plandai Biotechnology's Operating Margin % for the quarter that ended in Jun. 2023 was %.

Plandai Biotechnology's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Plandai Biotechnology's annualized ROC % for the quarter that ended in Jun. 2023 was -120.07%. Plandai Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.

Plandai Biotechnology Operating Income Historical Data

The historical data trend for Plandai Biotechnology's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Operating Income Chart

Plandai Biotechnology Annual Data

Trend

Mar09

Mar10

Mar11

Jun12

Jun13

Jun14

Jun15

Jun16

Jun22

Jun23

Operating Income

Get a 7-Day Free Trial

-4.74

-8.85

-3.11

-0.02

-0.71

Plandai Biotechnology Semi-Annual Data
	Mar03	Mar04	Mar05	Mar06	Mar07	Mar08	Mar09	Mar10	Mar11	Jun12	Jun13	Jun14	Jun15	Jun16	Jun22	Jun23
Operating Income	Get a 7-Day Free Trial											-4.74	-8.85	-3.11	-0.02	-0.71

Plandai Biotechnology Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.71 Mil.

Plandai Biotechnology (OTCPK:PLPL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Plandai Biotechnology's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.706 * ( 1 - 0% )	/	( (1.118	+	0.058)	/ 2 )
=	-0.706	/	0.588
=	-120.07 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0.408	-	( 0	-	max(0, 1.526	-	0	+	0	))
=	1.118

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0.385	-	( 0	-	max(0, 0.443	-	0	+	0	))
=	0.058

Note: The Operating Income data used here is one times the annual (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Plandai Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-19.773	/	( ( (0 + max(-1.411, 0))	+	(0 + max(-0.393, 0)) )	/	1 )
=	-19.773	/	( ( 0	+	0 )	/	1 )
=	-19.773	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.408	+	0	+	1.003)
=	-1.411

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.385	+	0	+	0.008)
=	-0.393

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Plandai Biotechnology's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-0.706	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Plandai Biotechnology Operating Income Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Plandai Biotechnology (Plandai Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

4811 49th Street, San Diego, CA, USA, 92115

Website

http://www.plandaibiotech.com

Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.

Executives

Callum Baylis-duffield	director	FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula	other: Former Director	175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson	director	P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield	director, officer: President, Secretary and CFO	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield	director	2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki	director	21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866